CD4 and leukemia: Ex vivo experiments have shown that CD4CAR NK-92 cells possess potent anti-tumor cytotoxicity against various adult and pediatric CD4+ lymphoma/leukemia cell lines, as well as primary CD4+ T-cell malignancies from both adult and pediatric patients.